Literature DB >> 17522146

Early onset vitreous amyloidosis in familial amyloidotic polyneuropathy with a transthyretin Glu54Gly mutation is associated with elevated vitreous VEGF.

T M O'Hearn1, A Fawzi, S He, N A Rao, J I Lim.   

Abstract

AIM: To report the early vitreous involvement in a rare familial amyloidotic polyneuropathy (FAP) mutation and associated vitreous vascular endothelial growth factor (VEGF) levels.
DESIGN: Observational case series.
METHODS: Review of clinical, pathological, photographic, and angiographic records of two FAP siblings with severe vitreous involvement. Laboratory ELISA analysis of vitreous samples for VEGF, and DNA sequence analysis of peripheral blood for transthyretin (TTR) mutational analysis.
RESULTS: Two patients underwent 25-gauge vitrectomy in three eyes with marked improvement of visual acuity. Neovascularisation seen intraoperatively responded to endolaser. Analysis of vitrectomy samples for VEGF showed raised levels in all three specimens. Mutational analysis revealed an isolated Glu54Gly mutation in the transthyretin gene.
CONCLUSIONS: Early involvement of the vitreous occurs in a rare transthyretin mutation of FAP, with increased vitreous levels of VEGF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522146      PMCID: PMC2095545          DOI: 10.1136/bjo.2007.119495

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Ocular amyloid involvement after liver transplantation for polyneuropathy.

Authors:  E Ando; Y Ando; K Haraoka
Journal:  Ann Intern Med       Date:  2001-11-20       Impact factor: 25.391

2.  An aggressive form of familial amyloid polyneuropathy caused by a Glu54Gly mutation in the transthyretin gene.

Authors:  H S Kim; S-M Kim; S-W Kang; S-C Jung; K-S Lee; T-S Kim; Y-C Choi
Journal:  Eur J Neurol       Date:  2005-08       Impact factor: 6.089

3.  Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion.

Authors:  Hidetaka Noma; Atsushi Minamoto; Hideharu Funatsu; Hidetoshi Tsukamoto; Kensuke Nakano; Hidetoshi Yamashita; Hiromu K Mishima
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-13       Impact factor: 3.117

4.  Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up.

Authors:  E Ando; Y Ando; R Okamura; M Uchino; M Ando; A Negi
Journal:  Br J Ophthalmol       Date:  1997-04       Impact factor: 4.638

5.  An inherited non-amyloidogenic transthyretin variant, [Ser6]-TTR, with increased thyroxine-binding affinity, characterized by DNA sequencing.

Authors:  N J Fitch; M T Akbari; D B Ramsden
Journal:  J Endocrinol       Date:  1991-05       Impact factor: 4.286

6.  Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis.

Authors:  M Brett; M R Persey; M M Reilly; T Revesz; D R Booth; S E Booth; P N Hawkins; M B Pepys; J A Morgan-Hughes
Journal:  Brain       Date:  1999-02       Impact factor: 13.501

Review 7.  Transthyretin mutations in hyperthyroxinemia and amyloid diseases.

Authors:  M J Saraiva
Journal:  Hum Mutat       Date:  2001-06       Impact factor: 4.878

8.  Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis.

Authors:  Elia J Duh; Hoseong S Yang; Julia A Haller; Eugene De Juan; Mark S Humayun; Peter Gehlbach; Michele Melia; Dante Pieramici; J B Harlan; Peter A Campochiaro; Donald J Zack
Journal:  Am J Ophthalmol       Date:  2004-04       Impact factor: 5.258

9.  A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation.

Authors:  Yukio Ando; Hisayasu Terazaki; Masaaki Nakamura; Eiko Ando; Katsuki Haraoka; Taro Yamashita; Mitsuharu Ueda; Hiroaki Okabe; Yutaka Sasaki; Hidenobu Tanihara; Makoto Uchino; Yukihiro Inomata
Journal:  Transplantation       Date:  2004-02-15       Impact factor: 4.939

10.  Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy.

Authors:  M M Reilly; D Adams; D R Booth; M B Davis; G Said; M Laubriat-Bianchin; M B Pepys; P K Thomas; A E Harding
Journal:  Brain       Date:  1995-08       Impact factor: 13.501

View more
  6 in total

Review 1.  Monitoring the Patient with Retinal Angiopathy Associated with Hereditary Transthyretin Amyloidosis: Current Perspectives.

Authors:  João Heitor Marques; João Coelho; Maria João Menéres; João Melo Beirão
Journal:  Clin Ophthalmol       Date:  2022-07-09

2.  Mutation p.G83R in the transthyretin gene is associated with hereditary vitreous amyloidosis in Han Chinese families.

Authors:  A-Mei Zhang; Hui Wang; Peng Sun; Qiu-Xiang Hu; Yuqing He; Yong-Gang Yao
Journal:  Mol Vis       Date:  2013-07-25       Impact factor: 2.367

3.  A woman with a rare p.Glu74Gly transthyretin mutation presenting exclusively with a rapidly progressive neuropathy: a case report.

Authors:  Anne Schänzer; Christoph Kimmich; Christoph Röcken; Thomas Haverkamp; Isabell Weidner; Till Acker; Heidrun H Krämer
Journal:  J Med Case Rep       Date:  2014-12-04

4.  Intravitreal bevacizumab upregulates transthyretin in experimental branch retinal vein occlusion.

Authors:  Lasse Jørgensen Cehofski; Anders Kruse; Alexander Nørgård Alsing; Jonas Ellegaard Nielsen; Shona Pedersen; Svend Kirkeby; Bent Honoré; Henrik Vorum
Journal:  Mol Vis       Date:  2018-11-26       Impact factor: 2.367

5.  Case Report: Hereditary transthyretin (ATTRv) amyloidosis: The p.G103R mutation of the transthyretin gene in a Han Chinese family is associated with vitreous hemorrhage.

Authors:  Junhui Shen; Hao Yu; Jijian Lin; Li Zhang; Xiaohong Pan; Zhiqing Chen
Journal:  Front Genet       Date:  2022-09-15       Impact factor: 4.772

6.  Macular and optic disc edema and retinal vascular leakage in familial amyloid polyneuropathy with a transthyretin Val30Met mutation: a case report.

Authors:  Arnaldo Dias-Santos; Joana Ferreira; João Paulo Cunha
Journal:  J Med Case Rep       Date:  2014-10-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.